PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to desc...

Full description

Bibliographic Details
Main Authors: Filipa Lynce, Mervat Saleh, Ayesha Shajahan-Haq, Christopher Gallagher, Asma Dilawari, Olwen Hahn, Maysa Abu-Khalaf, Ling Cai, Paula Pohlmann, Mahsa Mohebtash, Lois Kamugisha, Claudine Isaacs
Format: Article
Language:English
Published: Elsevier 2018-06-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865418300085

Internet

http://www.sciencedirect.com/science/article/pii/S2451865418300085

Similar Items